T-cell receptor modulators(Procept)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameT-cell receptor modulators(Procept)
Drug Alias NameCD3/Ti (Squibb)CD3/Ti (Procept)T-cell receptor modulators(Squibb)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionT cell surface glycoprotein CD3 stimulants
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsRejection of organ transplantationAutoimmune DiseasesLupus Erythematosus, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesWorld
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPaligent Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPaligent IncBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationAutoimmune DiseasesLupus Erythematosus, Systemic +[5] 

Other Information

ATC CodeN/A
Related LinksN/A